TechDogs-"JelloX Biotech Collaborates With Mayo Clinic To develop AI Enhanced 3D Pathology Imaging Technology"

Biotechnology

JelloX Biotech Collaborates With Mayo Clinic To develop AI Enhanced 3D Pathology Imaging Technology

By PR Newswire

PR Newswire
Overall Rating

HSINCHU, July 31, 2024 /PRNewswire/ -- JelloX Biotech Inc. ('JelloX') is pleased to announce that it has entered into a collaboration through a know-how agreement with Mayo Clinic to further develop and validate their 3D digital imaging and AI analysis technology. JelloX previously participated in the fifth cohort of the Mayo Clinic and Arizona State University Alliance for Health Care MedTech Accelerator, a flagship program providing early-stage medical device and healthcare technology companies with curriculum to accelerate their go-to-market plans. JelloX has developed a 3D pathology imaging technology with artificial intelligence (AI) for spatial analysis to support precision cancer diagnosis.

Cancer diagnosis using traditional 2D imaging methods can miss spatial relationships of critical tumor biomarkers and suffer from interpretive variability. JelloX's 3D imaging technology captures enhanced spatial context, providing a 3D view of tissue architecture that hopes to improve diagnostic accuracy and consistency and provide pathologists a more comprehensive diagnosis for cancer patients. Furthermore, the same biopsy tissue can then be analyzed by genomic sequencing and proteomics to provide patients with the full spectrum of precision medicine.

JelloX's CEO and founder, Dr. Yen-Yin Lin added, "Working with Mayo Clinic through this know-how collaboration and MedTech Accelerator has been an incredible journey for us. We are excited to bring our 3D pathology technology to research and clinical practice. Our goal is to provide researchers and clinicians with more precise diagnostic tools and to support pharmaceutical companies in their quest to develop new drugs to match patients with the right treatment at the right time." 

The collaboration is an example of how innovation and collaboration can collectively advance opportunities to improve healthcare outcomes for patients. As the field of pathology continues to evolve, the integration of digital solutions like JelloX's 3D pathology could contribute to the future of medical diagnostics and treatment.

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research. 

About JelloX 

JelloX, is at the forefront of innovation in the pathology space. Its patented 3D digital pathology tissue imaging with AI-empowered analysis translates into a precision diagnosis solution. The aim is to create the world's first 3D digital pathology solution in support of precision cancer diagnosis, optimize patient treatment outcome, and match the right patients with the right drugs at the right time. For more information, visit [JelloX Website].

CONTACT:

JelloX Biotech Inc.

https://jellox.com/

Tel: +886-3-6583058

Fax: +886-3-5620853

Email: sales@jellox.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/jellox-biotech-collaborates-with-mayo-clinic-to-develop-ai-enhanced-3d-pathology-imaging-technology-302210897.html

SOURCE JelloX Biotech Inc.

First published on Wed, Jul 31, 2024

Liked what you read? That’s only the tip of the tech iceberg!

Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!

Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.

Dive into TechDogs' treasure trove today and Know Your World of technology like never before!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Join The Discussion

- Promoted By TechDogs -

IDC MarketScape: Worldwide Modern Endpoint Security for Midsize Businesses 2024 Vendor Assessment

Join Our Newsletter

Get weekly news, engaging articles, and career tips-all free!

By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.

  • Dark
  • Light